ArticleInternational journal of general medicine2026
Immune Checkpoint Inhibitor Associated Myopathy with Concurrent Myocardial Injury: A Retrospective Cohort Study.
Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To characterize immune checkpoint inhibitor (ICI) myopathy complicated by myocardial injury. Methods: Retrospective analysis of 16 patients who were diagnosed with ICI myopathy complicated by myocardial injury at Beijing Tsinghua Changgung Hospital from 2020 to 2025. Results: The cohort comprised 16 patients (male:female ratio: 10:6; mean age 68 years) who developed at a median of 37 days after the initial immunotherapy. The initial clinical manifestations included ptosis in 43.8% (n=7) of the patients, bulbar muscle involvement in 12.5% (n=2), and respiratory muscle impairment in 18.8% (n=3). All patients demonstrated cardiac involvement. Laboratory findings revealed elevated creatine kinase (CK) levels (mean 2190.9 U/L), CK-MB isoenzyme (mean 79.1 ng/mL) and high-sensitivity troponin T levels (hs-TnT) (mean 1.077 ng/mL) in all patients. Anti-acetylcholine receptor antibody positivity was observed in 25% (1/4) and anti-titin antibody positivity in 50% (2/4) of the tested patients. Myopathic changes were identified in 50% of patients (3/6), and one patient exhibited a decremental response to low-frequency repetitive nerve stimulation with an incremental response to high-frequency stimulation. During the course of hormone therapy, we observed a previously unreported discordant phenomenon in 50% of patients (n=8), characterized by a rebound elevation in the CK-MB isoenzyme occurring concurrently with a gradual decline in total CK levels. Conclusion: ICI myopathy is a distinct immune-mediated disorder that emerges following cancer immunotherapy. It is characterized by skeletal and cardiac muscle involvement, with a hallmark clinical feature of nonfluctuating ptosis. It is particularly noteworthy that even patients presenting with mild clinical symptoms and only minor elevations in CK or cardiac enzymes should be carefully evaluated for electrocardiographic abnormalities and monitored for malignant arrhythmias. Early diagnosis, prompt intervention, and rigorous monitoring of laboratory parameters and cardiac rhythms during the acute phase are essential for improving outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.